Introgen says Advexin promising as breast-cancer treatment

By Elaine Rigoli

Tampa, Fla., Sept. 6 - Introgen Therapeutics, Inc. said Wednesday that results from a phase 2 study with Advexin therapy in the treatment of women with locally advanced breast cancer showed objective clinical responses with a greater than 50% reduction in tumor size.

The trial combined Advexin and chemotherapy in all of the patients. Complete tumor removal by subsequent surgery was achieved in 100% of the patients.

At a median follow-up of 37 months, the estimated breast cancer-specific survival rate was 84%. These results with Adevexin are better than what would be expected from chemotherapy treatment alone, the company said.

The Austin, Texas-based pharmaceutical company said the data suggests that Advexin may be combined with chemotherapy to improve patient outcomes and to enable less-invasive surgeries that facilitate breast conservation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.